Mda-7/Interleukin 24 (Il-24) in Tumor Gene Therapy: Application of Tumor Penetrating/Homing Peptides for Improvement of the Effects Publisher Pubmed

Summary: Review suggests targeting IL-24 to tumors could enhance cancer therapy. Can peptides improve delivery? #CancerTherapy #Cytokines

Rasoolian M¹ ; Kheirollahi M^{1, 2} ; Hosseini SY³
Source: Expert Opinion on Biological Therapy Published:2019

Abstract

Introduction: MDA-7/Interleukin-24 (IL-24), as a pleiotropic cytokine, exhibits a specific tumor suppression property that has attracted a great deal of attention. While its anti-tumor induction is mostly attributed to endogenous gene expression, attachment of secreted MDA-7/IL-24 to cognate receptors also triggers the death of cancerous cell via different pathways. Therefore, precise targeting of secreted MDA-7/IL-24 to tumor cells would render it more efficacy and specificity. Areas covered: In order to target soluble cytokines, particularly MDA-7/IL-24 to the neighbor tumor sites and enhance their therapeutic efficiency, fusing with cell penetrating peptides (CPPs) or Tumor homing peptides (THPs) seems logical due to the improvement of their bystander effects. Although the detailed anti-tumor mechanisms of endogenous mda-7/IL-24 have been largely investigated, the significance of the secreted form in these activities and methods of its improving by CPPs or THPs need more discussion. Expert opinion: While the employment of CPPs/THPs for the improvement of cytokine gene therapy is desirable, to create fusions of CPPs/THPs with MDA-7/IL-24, some hurdles are not avoidable. Regarding our expertise, herein, the importance of CPPs/THPs, needs for their elegant designing in a fusion structure, and their applications in cytokine gene therapy are discussed with a special focus on mda-7/IL-24. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.